Lundbeck begins clinical development of yet another potential new treatment of Parkinson’s disease

New treatment might have the potential to slow or stop the progression of Parkinson’s disease.

VALBY, 12-Sep-2018 — /EuropaWire/ — H. Lundbeck A/S (Lundbeck) begins clinical development of yet another potential new treatment of Parkinson’s disease with the enrollment of the first participant in a phase I study with the compound Lu AF82422.

Lu AF82422, which was invented by Lundbeck in collaboration with Genmab, is the first antibody ever that Lundbeck brings into clinical development. In the phase 1 study it will be studied in both healthy volunteers and patients with Parkinson’s disease.

Lu AF82422 is a human antibody targeting the toxic proteins causing the death of brain cells that leads to Parkinson’s disease. The compound is thought to work like the body’s natural antibodies when the immune system works to remove harmful proteins. As it targets the underlying biology of the disease, Lu AF82422 may potentially not only treat its symptoms, but might also slow or stop its progression.

“We are excited to start the clinical development of this highly innovative potential treatment. The biologic approach may potentially enable to us to provide a much better treatment than what is available today”, says Anders Gersel Pedersen, Executive Vice President, Research and Development at Lundbeck.

Lu AF82422 is the third potential new treatment of Parkinson’s disease that Lundbeck adds to its clinical pipeline in 2018 following the inclusion of Lu AF28996 and foliglurax. Further to this, Lundbeck in May started clinical development of Lu AF76432 for the treatment of schizophrenia and Alzheimer’s disease, meaning that a total of four new compounds has been added to the pipeline this year.
Contacts

Mads Kronborg
Senior Director, Corporate Communication
Phone: +45 36 43 40 00
E-mail: mavk@lundbeck.com
About Lundbeck

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in psychiatric and neurological disorders. For more than 70 years, we have been at the forefront of research within neuroscience. Our key areas of focus are depression, schizophrenia, Parkinson’s disease and Alzheimer’s disease.

An estimated 700 million people worldwide are living with psychiatric and neurological disorders and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with psychiatric and neurological disorders – we call this Progress in Mind.
Read more at www.lundbeck.com/global/about-us/progress-in-mind.

Our approximately 5,000 employees in more than 50 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several late-stage development programmes and our products are available in more than 100 countries. Our research centre is based in Denmark and our production facilities are located in Denmark, France and Italy. Lundbeck generated revenue of DKK 17.2 billion in 2017 (EUR 2.3 billion; USD 2.6 billion).

For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Twitter at @Lundbeck.

SOURCE: H. Lundbeck A/S